忍者ブログ

ニュースリリースのリリースコンテナ第二倉庫

ニュースサイトなど宛てに広く配信された、ニュースリリース(プレスリリース)、 開示情報、IPO企業情報の備忘録。 大手サイトが順次削除するリリースバックナンバーも、蓄積・無料公開していきます。 ※リリース文中の固有名詞は、発表社等の商標、登録商標です。 ※リリース文はニュースサイト等マスコミ向けに広く公開されたものですが、著作権は発表社に帰属しています。

2025'01.31.Fri
×

[PR]上記の広告は3ヶ月以上新規記事投稿のないブログに表示されています。新しい記事を書く事で広告が消えます。

2007'09.12.Wed
Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
September 10, 2007


    HILTON HEAD ISLAND, S.C., Sept. 10 /Xinhua-PRNewswire/
-- At approximately 3:21 PM today, Dr. Roger Kenneth
Hershline PhD MD, Chairman and Founder of CureHIV.us,
agreed to act as a conduit to provide samples of Global
Humanceuticals, Inc's., new extremely effective, safe and
stable drug candidate to profit, non-profit, academic,
government, non-government, U.S. and foreign institutions,
organizations, and corporations, under mutual agreements,
contracts or partnerships, to spur theoretical, objective,
mechanistic, developmental or clinical research. This
unique new chemical entity is referred to as compound NIAID
#11039. However, this invention has already received a
patent called: Antiviral Composition, U.S. patent number:
6,821,958 on November 23, 2004. The World International
Patent Organization published the International Application
Number as PCT/US2005/039528 on November 5, 2006.

    "This gift is intended to extend technology that
no one else posses on this planet." Stated Dr.
Hershline. "Already, Chinese scientists are very
interested."  Dr. Hershline hosted Session V at the
World Aids Day Conference China Dec 1 to Dec 3, 2006, to
initially present data an NIAID #11039.  There was,
unfortunately, a communication error from the National
Institute of Health (NIH of the United States) to Dr.
Hershline, which prevented presentation of test results.  

    The compound has a non-toxic alpha-glucose backbone,
obtained from an abundant natural source.  The backbone is
chemically bi-substituted in a random fashion, by a new
reaction.  "The substitution groups are different
sulfur based viral de-activating groups that work together
to provide viral entry inhibition at concentrations of one
pico-Molar.  This active concentration is equivalent to
diluting a 1% solution one million times.   

    The random substitutions are intended to prevent the
virus from escaping de-activation thru mutation. 
"Global Humanceuticals, Inc.'s NIAID #11039 is the
first drug designed to prevent the development of
resistance, the biggest nightmare in HIV treatment,"
stated Dr. Hershline.

    "I think we have to talk in terms of a cure for
HIV.  I want to cure HIV and that is why my foundation is
called CureHIV.us," concluded Dr. Hershline.

    Interested parties can contact Dr. Roger Kenneth
Hershline PhD MD thru CureHIV.us Headquarters by email:
Roger@CureHIV.us, mail P.O. Box 23467, Hilton Head Is., SC,
29925, by fax: 843-342-5924, phone:  843-342-5900.  Direct
to Dr. Hershline:  843-683-3683. 


    For more information, please contact:

     Dr. Roger Kenneth Hershline PhD MD
     CEO of Global Humanceuticals, Inc.
     Tel:    +1-843-342-5900
     Direct: +1-843-683-3683
     Fax:    +1-843-342-5924
     Email:  Roger@CureHIV.us 
     Web:    http://www.curehiv.us 

PR
Post your Comment
Name:
Title:
Mail:
URL:
Color:
Comment:
pass: emoji:Vodafone絵文字 i-mode絵文字 Ezweb絵文字
trackback
この記事のトラックバックURL:
[13456] [13455] [13454] [13453] [13452] [13451] [13450] [13449] [13448] [13447] [13446
«  BackHOME : Next »
広告
ブログ内検索
カウンター

忍者ブログ[PR]